Skip to main content

Table 1 Hospital mortality risk factors (number (%) or median (IQR))

From: Candidemia in critically ill immunocompromised patients: report of a retrospective multicenter cohort study

Clinical features

Total

N = 121

Dead

N = 73

Alive

N = 48

p value

Female gender

47 (39%)

24 (33%)

23 (48%)

0.13

Age

60 (49–66)

60 (49–65)

61 (52–68)

0.3

Median year of ICU admission (IQR)

2013 (2010–2015)

2013 (2010–2016)

2013 (2010–2015)

0.86

Underlying immunosuppression

 Solid tumors

36 (30%)

19 (26%)

17 (35%)

0.31

 Hematological malignancy

81 (67%)

52 (71%)

29 (60%)

0.24

 Allogenic SCT

8 (7%)

7 (10%)

1 (2%)

0.14

 Acute myeloid leukemia

17 (14%)

10 (14%)

7 (15%)

1

 Acute lymphoid leukemia

9 (7%)

7 (10%)

2 (4%)

0.32

 Lymphoma

45 (37%)

29 (40%)

16 (33%)

0.56

 Myelodysplasia

6 (5%)

4 (5.5%)

2 (4%)

1

 Autoimmune disease

13 (11%)

7 (10%)

6 (12.5%)

0.77

 HIV infection

19 (16%)

11 (15%)

8 (17%)

0.80

 Neutropenia

58 (49%)

37 (51%)

21 (46%)

0.71

ICU features

 SOFA score

10 (6–15)

12 (8–16)

8 (5–14)

0.011

 Surgical patient

25 (21%)

15 (20%)

10 (21%)

1

 Renal replacement therapy

71 (61%)

50 (68.5%)

22 (46%)

0.005

 Invasive mechanical ventilation

91 (75%)

61 (85%)

31 (65%)

0.015

 Vasopressors

66 (54.5%)

45 (62%)

21 (44%)

0.06

Candidemia features

 Antifungal prophylaxis

20 (17%)

16 (22%)

4 (8%)

0.08

 ICU acquired candidemia

70 (58%)

44 (63%)

26 (54%)

0.5

 Candida albicans

65 (54%)

39 (53%)

26 (54%)

1

 Candida glabrata

23 (19%)

13 (18%)

10 (21%)

0.81

 Candida tropicalis

13 (11%)

9 (12%)

4 (8%)

0.56

 Candida krusei

9 (7%)

7 (10%)

2 (4%)

0.32

 Candida parapsilosis

9 (7%)

5 (7%)

4 (8%)

0.74

 Fluconazole susceptibility

61 (70%)

35 (71%)

27 (69%)

1

 Echinocandins susceptibility

73 (92%)

39 (89%)

34 (97%)

0.22

 Adequacy of first AF therapy

78 (90%)

43 (86%)

36 (94%)

0.29

 CVC removed

103 (97%)

61 (98%)

42 (95.5%)

0.57

 Days to first AF therapy (IQR)

3 (1–3)

3 (1–3)

3 (1–3)

0.45

 Preemptive antifungal therapy

27 (22%)

16 (22%)

11 (23%)

1.00

  1. Adequacy is based on antifungal susceptibility of involved Candida based on MIC
  2. ICU intensive care unit, IQR interquartile range, SCT stem cell transplantation, AF antifungal therapy, CVC central venous catheter